
Blood pressures rise as the FDA cracks down on this wearable's flagship feature
TL;DR The FDA has scrutinized Whoop for a new wellness monitoring feature that has not been certified.
The FDA considers the Whoop MG (Medical Grade) a medical device and should remove the Blood Pressure Insights feature until approved.
Whoop claims the product is not for medical use and will not disable the feature.
Wellness wearable maker Whoop, specifically one of its latest fitness bands, has drawn the ire of the FDA after it debuted a feature not approved or certified by the authority.
Per a Bloomberg filing, the FDA is pressuring Whoop to disable its Blood Pressure Insights feature. This new app offers its wearers blood pressure estimates and related guidance to provide a holistic view of their well-being. However, the FDA and Whoop can't seem to agree whether the MG's feature constitutes a medical device and must go through the traditional regulatory channels.
WHOOP
Whoop's marketing material claims that the MG is 'not a medical device and cannot diagnose or manage medical conditions,' and, as a result, the FDA has no authority to 'regulate the product.' However, the FDA seemingly believes otherwise, claiming that potentially erroneous blood pressure readings can harm those wearing the device. Regardless, Whoop reportedly has confirmed that it would not remove the feature, going against the recent trends of health tech firms relenting to the agency.
Don't want to miss the best from Android Authority? Set us as a preferred source in Google Search to support us and make sure you never miss our latest exclusive reports, expert analysis, and much more.
Medical devices must go through the relevant FDA channels for testing and approval before being marketed and sold; this includes unproven and novel sensors on smartwatches and fitness trackers. While the process ensures consumers are offered clinically-approved products, it can take months, often resulting in features launching well after a device has debuted. The Fitbit Sense's ECG sensor is a particularly memorable example of this. The FDA can demand fines from offending companies or even forbid their products from being sold. Still, the genuine issue appears to be the nebulous definitions of medical devices and modern fitness trackers.
We've seen wellness wearable makers debut numerous features in recent years, but blood pressure readings and guidance remain relatively novel. The Samsung Galaxy Watch line and Garmin products like the Index include similar features, but both Korean and American companies have undergone the relevant approval processes before launch.
Despite its firm stance, Whoop has reportedly requested an audience with the FDA to clarify the situation, but it's unclear how this tussle will ultimately affect Whoop MG owners.
The screenless wellness band debuted for $359 alongside the Whoop 5.0 in May, but the Blood Pressure Insights feature is available only to premium subscribers.
Follow
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
GoDaddy Inc. (GDDY): Jim Cramer Is Surprised At Morgan Stanley's Report
We recently published . GoDaddy Inc. (NYSE:GDDY) is one of the stocks Jim Cramer recently discussed. GoDaddy Inc. (NYSE:GDDY) is an internet company that enables businesses to establish an online presence by setting up their websites. Its shares have lost 28% year-to-date after suffering from a steep 14% drop in February and an 11% dip in August. GoDaddy Inc. (NYSE:GDDY)'s shares fell in February after a fourth quarter revenue dip, while the August drop was driven by a weak EPS number, which beat analyst estimates by a rather modest three cents. Cramer discussed Morgan Stanley's decision to include GoDaddy Inc. (NYSE:GDDY) on its list of firms at risk from AI-led disruption, as he mentioned the firm's advertisement with actor Walton Goggins: '[On being included in Morgan Stanley's basket of companies at AI risk] Oh come on, Goggins, man!' Copyright: rawpixel / 123RF Stock Photo Here are Cramer's earlier thoughts about GoDaddy Inc. (NYSE:GDDY): 'As did by the way GoDaddy. . . I have GoDaddy on, I was kind of like, wow, that happened fast. While we acknowledge the potential of GDDY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
24 minutes ago
- Yahoo
Amazon.com, Inc. (AMZN): Jim Cramer Maintains It Needs To Buy NVIDIA
We recently published . Inc. (NASDAQ:AMZN) is one of the stocks Jim Cramer recently discussed. Inc. (NASDAQ:AMZN) is struggling on the stock market lately as investors are worried about the growth prospects of its cloud computing division. The shares have gained a mere 1.4% over the past month, after they fell by 9.6% after the firm's second quarter earnings were accompanied by weak AWS growth. Cramer continues to maintain that Inc. (NASDAQ:AMZN) is struggling because it is focusing on its in-house AI chips instead of NVIDIA's AI GPUs: 'Think about what happened to Amazon, when they decided to go away from using all the NVIDIA that was possible. . . Copyright: veghsandor / 123RF Stock Photo Here are his previous thoughts about Inc. (NASDAQ:AMZN): 'We're in the era, this is what happens, The two big overhangs in this market had been Apple waiting for the sword of Damocles and Amazon, trading down because Amazon Web Services is viewed as a share donor. Both of those seem to have been forgotten. David, the forgotten negatives there has been replaced by we're dumping the big tariffs for now.' While we acknowledge the potential of AMZN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
24 minutes ago
- Yahoo
Cerence Inc. (CRNC) Might Be A Hidden Gem, Says Jim Cramer
We recently published . Cerence Inc. (NASDAQ:CRNC) is one of the stocks Jim Cramer recently discussed. Cerence Inc. (NASDAQ:CRNC) is a software company that caters to the needs of the transportation industry. Its shares have gained 60% year-to-date and gained an unbelievable 45% in August. Cerence Inc. (NASDAQ:CRNC) is benefiting from the AI wave through having landed major deals, such as a partnership with Mercedes-Benz. Cramer discussed the firm in the context of it being an outlier that could be interesting in the AI era: 'I'm doing a piece about Cerence tonight. People are going to want to find out what I'm saying there. There's a lot of technology away from these big companies that is better than the big companies.' Copyright: audioundwerbung / 123RF Stock Photo Here are Cramer's previous thoughts about Cerence Inc. (NASDAQ:CRNC): 'I like Cerence, and I also happen to like Brian Krzanich, the CEO. I am partial. They make money. I think you've got a winner. I was actually trying to figure out whether I could justify doing a piece on it because it's not that expensive. Cerence is a winner, and Brian's always welcome on the show, as we know.' While we acknowledge the potential of CRNC as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data